So – I am the proud shareholder of 405 shares of Sangamo Therapeutics (NASDAQ: SGMO). Sangamo Therapeutics is a developmental biotechnology company and a pioneer in gene editing, gene sequencing and gene therapy.
The company has been around for almost 30 years, and has been a disappointment for the most part.
Sangamo is the only company in the US that has actually applied gene editing in a human. Tomorrow, Thursday, February 7, at 11:00 a.m., they will discuss the initial results from the trial.
The stock price is at $11.83 as of this writing. Incidentally, I own at around $22 – ouch! Nevertheless, tomorrow could change everything if the results are good.
My prediction is as follows:
Good results: Stock price doubles, maybe triples
Not good results: Stock down to $5 or less
So the risk/reward is huge.
I’m a little nervous because the company has disappointed investors in the past.
However, I’m a risk taker, and I can live with the results.
Wish Sangamo and me luck!
Disclaimer/Disclosure Statement: Information in this article is not intended to be a recommendation to invest in any stock. Rather, it is presented for readers’ education and consideration when making their own investment decisions. The author is long SGMO.
Click the image of the book at left to be taken to its Amazon page. (Disclosure: As a participant in the Amazon Services LLC Associates Program, I earn a small commission on each sale generated through these links.)